Navigation Links
Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial
Date:9/4/2009

STOCKHOLM, September 4 /PRNewswire/ -- Karolinska Development (publ) today announced that one of its portfolio companies, Dilafor AB, has concluded an extensive clinical study of its candidate drug, tafoxiparin, a new drug substance for the prevention of protracted labor during childbirth. The promising results of the Phase II trial bring the project closer to exit in line with Karolinska Development's business strategy.

Dilafor's candidate drug, tafoxiparin DF01 is one of 11 compounds within the Karolinska Development portfolio that are currently conducting clinical trials. The completion of the Dilafor study is an important milestone for Karolinska Development and exemplifies the company's ability to develop innovative ideas through to clinical proof of concept quickly and efficiently. In the case of Dilafor, tafoxiparin has taken just six years to go from research concept to its current stage.

Karolinska Development's portfolio consists of more than 40 life science companies. A unique business model, which gives portfolio companies access to a broad network of business, legal, regulatory and scientific expertise, means that development times and costs are reduced compared to traditional drug development programs. With seven compounds currently undergoing Phase II clinical trials and five in Phase I the portfolio has matured to the point that Karolinska Development is now actively seeking commercial partners for its most advanced projects.

Conny Bogentoft, CEO of Karolinska Development, said, "The completion of the Dilafor Phase II trial is an important step for Karolinska Development and we are extremely pleased that Dilafor has achieved some very positive results. At the same time, it also goes a long way towards validating our business model. We are now very much focused on finding commercial opportunities for Dilafor's tafoxiparin and for several of our other projects that are reachin
'/>"/>

SOURCE Karolinska Development AB PUBL
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Karolinska Development Strengthens its Management Team With the Appointment of Dr Carl Harald Janson
2. Karolinska Development Closes Fully Subscribed New Share Issue
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
5. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
6. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
7. Global Experts Explore Entire Spectrum of Aids Vaccine Development
8. Vical Names Andrew de Guttadauro Vice President, Corporate Development
9. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
10. SemBioSys updates Apo AI development program
11. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)...  Orexigen Therapeutics, Inc. (Nasdaq: OREX ) will ... Friday, May 8 before the market opens. The announcement ... call at 8:30 a.m. Eastern Time (5:30 a.m. Pacific ... by phone by calling (800) 708-4540 (domestic) or (847) ... accessed live on the Investors section of the Orexigen ...
(Date:5/5/2015)... Claremont, CA (PRWEB) May 05, 2015 ... Lonnissa Nguyen, PhD as Regulatory Affairs Manager. , Dr. ... at an important juncture for the company as it ... new drug products over the next two years. Dr. ... submission of all the regulatory key documents that must ...
(Date:5/4/2015)... May 4, 2015   St. Jude Children,s ... better computer tool for finding genetic alterations that ... were difficult to identify with whole-genome sequencing. The ... Nature Methods . The tool is ... Segmentation by Regression Tree in Next Generation Sequencing. ...
(Date:5/4/2015)... /PRNewswire/ - The Fight Against Cancer Innovation Trust ... the formation of Turnstone Biologics Inc. (Turnstone), a ... that harness the patient,s own immune system. ... the Children,s Hospital of Eastern Ontario ... Ontario Institute for Cancer Research (OICR), the Ottawa ...
Breaking Biology Technology:Synedgen Announces the Appointment of Regulatory Affairs Manager 2Scientists dramatically improve method for finding common genetic alterations in tumors 2Scientists dramatically improve method for finding common genetic alterations in tumors 3Scientists dramatically improve method for finding common genetic alterations in tumors 4Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 2Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 3
... Johnson Controls, Inc. is introducing a new building ... Authorized Building Control Specialist (ABCS) network. , ,The Facility ... is scalable to provide control to a wide variety ... quick access to information from anywhere in the system, ...
... sector, she began to notice a certain pattern: Scientists with ... business world to be a much different place than academia, ... ,"Along the way, I realized that it was that people ... product just as effectively as a competitor," Villars said. "I ...
... suburban Madison will gain early review and easier access ... Alumni Research Foundation (WARF) has available for licensing, under ... Promega announced Tuesday. , ,If Promega finds a ... makes it easier to license the technology and develop ...
Cached Biology Technology:Can tech people be business leaders? Upcoming seminar may have the answer 2Can tech people be business leaders? Upcoming seminar may have the answer 3Promega to get early access to WARF technologies under new agreement 2
(Date:4/13/2015)... a leading cloud-based consumer engagement platform that provides trusted ... communities around health and wellness, announced today the launching ... The ... vehicle to receive validated health information from consumers. ... will allow higi,s trusted partners, on a user opt-in ...
(Date:4/2/2015)... April 2, 2015 In ... by far outperforms the strongest competitors, showing outstanding ... accuracy, the system is capable of a throughput ... proves up to be ten times faster than ... runner-up performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, the ... users across iOS and Android ... integrating biofeedback into the platform to allow patients to ... For the first time, patients will be able to ... dose impacts important biometrics, such as glucose levels and ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... Inc., announced today that it will receive a tuberculosis ... Foundation,s Grand Challenges in Global Health program, an initiative ... tools that can radically improve health in the developing ... Group at SomaLogic, will pursue an innovative research project ...
... psychologists at The University of Nottingham has shown that babies ... to develop healthier food preferences and are less likely to ... food. The research just published by BMJ Open ... on food preferences and Body Mass Index in early childhood ...
... (Feb. 9, 2012) Aging takes its toll on sex ... Baylor College of Medicine and the University of ... diminishes the come-hither effect of the chemicals of love ... evidence that the pheromones produced at these different ages affect ...
Cached Biology News:SomaLogic Inc. receives Grand Challenges tuberculosis biomarkers grant 2Baby knows best! Study shows baby-led weaning promotes healthy food preferences 2Baby knows best! Study shows baby-led weaning promotes healthy food preferences 3Fruit flies drawn to the sweet smell of youth 2
... serum is collected from fasted Rhesus monkeys of ... Available Anticoagulants: N-02: Citrate ... K2EDTA N-08: Potassium Oxalate N-10: ... N-05: ACD N-07: CPD ...
Porcine Serum US Origin 6 Months or Older...
SEQUENASE PCR PRODUCT PRE-SEQU, 1 EA. Category: SEQUENASE....
... is collected off the clot from fasted Cynomolgus monkeys ... Available Anticoagulants: N-02: Citrate ... N-08: Potassium Oxalate N-10: EDTA (Na) ... N-07: CPD N-09: K3EDTA N-11: ...
Biology Products: